公司资料
BioAtla, Inc. 股价、新闻与催化剂
- 股票代码:
- BCAB
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
3.18 USD (0.00%)
收盘价
最后更新: 2026年8月21日
5.85M USD
市值
股价为何变动
As of Aug 21, 2026, BCAB was little changed and closed at $3.18. No new same-company headline was identified in the current news window.
公司概览
Conditionally Active Biologics
BioAtla develops antibodies engineered to bind preferentially under conditions found in the tumor microenvironment. The CAB platform uses factors such as acidic pH to reduce target binding in normal tissue and potentially limit on-target, off-tumor toxicity.
BA3182
BA3182 is a conditionally active EpCAM and CD3 bispecific T-cell engager in Phase 1 development for advanced adenocarcinomas. Both binding arms are designed to activate preferentially within tumors.
Antibody-Drug Conjugates
The clinical ADC portfolio includes ozuriftamab vedotin against ROR2 and mecbotamab vedotin against AXL. Programs have been studied in oropharyngeal cancer, sarcoma and KRAS-mutant lung cancer.
Broader CAB Pipeline
Evalstotug is a conditionally active CTLA-4 antibody, while preclinical assets target Nectin-4, B7H4, B7H3, EGFR and Trop2. BioAtla is evaluating strategic transactions and may alter the pace or scope of these programs while preserving capital.
未来催化剂
- BioAtla’s catalysts are conditional-activation antibodies and any oncology update that shows the platform can still differentiate. The company remains data-sensitive because the platform story is not yet fully proven.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。